New therapeutic techniques like phages and vaccines face the same fundamental problem as traditional antibiotics: if they're working well, they're used just once, which makes it difficult to make money.
像噬菌体和疫苗这样的新治疗技术面临着和传统抗生素一样的困境:如果它们有效,那么使用一次就够了,制药公司因此难以盈利。